Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential

  • Ther Adv Hematol. 2016 Jun;7(3):171-4. doi: 10.1177/2040620716636541.
Madeleine Duvic  1 ,  Mark Evans  2 ,  Casey Wang  3
Affiliations
  • 1. Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • 2. University of Utah School of Medicine, Salt Lake City, UT, USA.
  • 3. Department of Dermatology, The University of Texas MD Anderson Cancer Center, Pickens Tower, FCT11.6097, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
PMID: 27247757 DOI: 10.1177/2040620716636541
Abstract

Mogamulizumab (KW-0761) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets CC Chemokine Receptor 4 (CCR4). It has shown promising therapeutic potential in phase I and II clinical trials and is currently being investigated for efficacy in treating cutaneous T-cell lymphoma (CTCL). We review the mechanism of action of mogamulizumab and its role in treating CTCL. We also discuss the results of major clinical trials.

Keywords
cutaneous T-cell lymphoma; mogamulizumab; peripheral T-cell lymphoma.
Products